Outsourcing and regulatory pressure drive growth in trial sector, Bilcare GCS

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial

Bilcare GCS, the clinical supplies arm of Indian packaging giant Bilcare, has considerably expanded its Phase III trial offering in an effort to provide drugmakers with a complete package.

In an interview with in-PharmaTechnologist.com, Deborah Buscarino, director of marketing and communications at Bilcare Global Clinical Supplies (GCS) set out some of the reasons behind the expansion.

Buscarino said that the primary motivations had been: “The increasing outsourcing trend by large Pharma combined with increasing regulatory pressures driving an increase in number and size of clinical trials and globalization of clinical trials​.”

Clinical trials have grown increasingly global, larger and more complex. Government regulations are progressively more stringent, requiring more studies with larger patient populations. To register such large numbers of patients in minimal time and in competition with other companies often requires population sets that span multiple countries.

Buscarino added that: “The healthcare industry is growing rapidly due to greater life expectancy leading to greater incidence of chronic and degenerative diseases, advances in medical technology that continue to improve the survival rate of severely ill patients, who will then need extensive therapy, care and new technologies that enable the identification and treatment of conditions not previously treatable.

In order to maximise profits and maintain comparative positions, pharmaceutical and biotech companies must continue to identify and test new patentable products that can eventually be brought to market​.”

Expansion of Kalish bottling lines

Regarding the specific additions to Bilcare’s offering, Buscarino explained that the firm has: “reconfigured its [Kalish] bottling line and has improved its overall compliance posture by re-executing key validation packages on each of the bottling lines' individual components and by successfully executing a more robust performance qualification​.”

She confirmed that a major part of the expansion is the integration of a Pentpack CT1200L EAS unit dose blister packaging machine, which she said: “epitomises the flexibility required to excel in the demanding and dynamic realm of clinical supplies.”

With a single machine, Bilcare is able to run almost any type of thermo formed film as well as cold form. Whether we choose to operate the machine with the manual feed table that is capable of filling up to four different products simultaneously, or we choose to engage the powerful Fleximation Trialpack PC controller and automatically dose two different products in any desired configuration​.”

Buscarino highlighted the unit’s ability to share tooling with Bilcare’s existing Klockner EAS machine and that it can print on either the inside or the outside of the blister packages, which in some cases can negate the need for timely and costly carding operations, as key advantages offered by the apparatus.

She maintained however that: “Some of the most tangible benefits that this machine provides are quality related, such as the full colour vision systems that are integrated with the Trialpack Designer II… software that provide a level of comfort and safety by ensuring a correct and complete filling operation.

Another valuable benefit is the automatic pinhole detection and rejection system which virtually eliminates the risk of undetected breaches in the integrity of the blister cavity which are so critical for the performance of sensitive drug products​.

Buscarino concluded that as a result of its expanded offering: “Bilcare GCS is a one-stop shop for [customers], providing end-to-end clinical trial services - from formulation development and manufacturing, analytical, packaging and labeling, to storage and distribution, and IVRS. We also offer strategic in-sourcing to key customers​.”

Related topics Globalization Phase III-IV

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more